Marcelo Dantas Tavares de Melo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Marcelo Dantas Tavares de Melo has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Vera Maria Cury Salemi
Hospital Sirio Libanes, Brasil
4 shared publications - Charles Mady
Universidade de São Paulo, Brasil
2 shared publications - Fernando Freitas de Oliveira
Heart Institute
2 shared publications - Érika Alves da Silva
Universidade Federal da Paraíba
2 shared publications - Ariane Vieira Scarlatelli Macedo
Faculdade de Ciências Médicas de Santa Casa de São Paulo, Brasil; Instituto Lado a Lado pela Vida, Brasil
1 shared publication - Breno Moreno de Gusmão
Department of Onco-Hematology, Beneficência Portuguesa Hospital, São Paulo, Brazil
1 shared publication
Latest Publications
- Open Access
- 19 March 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 38 (1)
Association of Noonan Syndrome, Noncompaction of the Myocardium, Hypertrophic Cardiomyopathy, and Long QT Syndrome: A Case Series
Background: The Noonan syndrome (NS) is a rare genetic disorder characterized by manifestations such as short stature, a webbed neck,
- 19 March 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 38 (1)
Open AccessAssociation of Noonan Syndrome, Noncompaction of the Myocardium, Hypertrophic Cardiomyopathy, and Long QT Syndrome: A Case Series
Background: The Noonan syndrome (NS) is a rare genetic disorder characterized by manifestations such as short stature, a webbed neck,
- Open Access
- 19 March 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 38 (1)
Associação da Síndrome de Noonan, Miocárdio não Compactado, Cardiomiopatia Hipertrófica e Síndrome do QT Longo: Uma Série de Casos
Introdução: A síndrome de Noonan (SN) é uma doença genética rara caracterizada por manifestações como baixa estatura, pescoço alado, micrognatia e hipertelorismo. Embora a SN predisponha a distúrbios cardíacos, como a cardiomiopatia hipertrófica (CMH), sua associação com o miocárdio não compactado (MNC) é rara. O MNC é uma anomalia embriológica marcada por trabeculação excessiva e formação de recessos miocárdicos profundos, cuja apresentação clínica varia de assintomática a eventos tromboembólicos graves. Este estudo visa descrever as alterações e os desfechos cardiovasculares em portadores de SN e MNC acompanhados no serviço de cardiologia de um hospital brasileiro. Metodologia: Trata-se de um estudo observacional, longitudinal e prospectivo, envolvendo o acompanhamento de três pacientes adultos com fenótipo de SN. Os pacientes foram avaliados por meio de ecocardiograma e ressonância magnética cardíaca (RMC). Dados como idade, sexo, histórico familiar, início dos sintomas e desfechos, como eventos tromboembólicos, transplante cardíaco (TxC) e óbito, foram analisados. Resultados: Todos os três pacientes acompanhados (dois homens e uma mulher, irmã de um dos homens) apresentavam MNC com disfunção ventricular. A paciente do sexo feminino também apresentava síndrome do QT longo (SQTL). Todos desenvolveram trombo apical, sendo dois casos no ventrículo esquerdo (VE). A paciente do sexo feminino foi submetida a TxC, enquanto os dois homens faleceram após quadro de descompensação e evolução para choque cardiogênico. Conclusão: Este estudo ressalta a necessidade de diagnóstico precoce e triagem familiar em pacientes com SN, visando à otimização do tratamento e à melhora prognóstica. Não há registro na literatura de associação de todas as patologias descritas em um mesmo paciente.
- 19 March 2025
- Published by Sociedade Brasileira de Cardiologia in ABC Imagem Cardiovascular
- Vol. 38 (1)
Open AccessAssociação da Síndrome de Noonan, Miocárdio não Compactado, Cardiomiopatia Hipertrófica e Síndrome do QT Longo: Uma Série de Casos
Introdução: A síndrome de Noonan (SN) é uma doença genética rara caracterizada por manifestações como baixa estatura, pescoço alado, micrognatia e hipertelorismo. Embora a SN predisponha a distúrbios cardíacos, como a cardiomiopatia hipertrófica (CMH), sua associação com o miocárdio não compactado (MNC) é rara. O MNC é uma anomalia embriológica marcada por trabeculação excessiva e formação de recessos miocárdicos profundos, cuja apresentação clínica varia de assintomática a eventos tromboembólicos graves. Este estudo visa descrever as alterações e os desfechos cardiovasculares em portadores de SN e MNC acompanhados no serviço de cardiologia de um hospital brasileiro. Metodologia: Trata-se de um estudo observacional, longitudinal e prospectivo, envolvendo o acompanhamento de três pacientes adultos com fenótipo de SN. Os pacientes foram avaliados por meio de ecocardiograma e ressonância magnética cardíaca (RMC). Dados como idade, sexo, histórico familiar, início dos sintomas e desfechos, como eventos tromboembólicos, transplante cardíaco (TxC) e óbito, foram analisados. Resultados: Todos os três pacientes acompanhados (dois homens e uma mulher, irmã de um dos homens) apresentavam MNC com disfunção ventricular. A paciente do sexo feminino também apresentava síndrome do QT longo (SQTL). Todos desenvolveram trombo apical, sendo dois casos no ventrículo esquerdo (VE). A paciente do sexo feminino foi submetida a TxC, enquanto os dois homens faleceram após quadro de descompensação e evolução para choque cardiogênico. Conclusão: Este estudo ressalta a necessidade de diagnóstico precoce e triagem familiar em pacientes com SN, visando à otimização do tratamento e à melhora prognóstica. Não há registro na literatura de associação de todas as patologias descritas em um mesmo paciente.
- Open Access
- 23 April 2020
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 21 (5) , 1-18
Advances in the Treatment of Cardiac Amyloidosis
Opinion statement: Cardiac amyloidosis is associated with a high mortality rate, a long delay between the first signs and the diagnosis but a short interval between diagnosis and death. This scenario has changed recently due to improved disease awareness among doctors and significant progress in diagnosis thanks to multimodal imaging and a multidisciplinary approach. Therefore, during the last few years, we have had access to specific therapies for those patients. Those therapies are quite different depending on the type of amyloidosis, but there has been real progress. Systemic light chain amyloidosis (AL) with cardiac involvement is the most common form of cardiac amyloidosis. The severity of heart disease dictates the prognosis in AL amyloidosis. Advances in chemotherapy and immunotherapy that suppress light chain production have improved the outcomes. These recent improvements in survival rates have enabled therapies such as implanted cardiac defibrillators and heart transplantation that were usually not indicated for patients with advanced light chain amyloid cardiomyopathy to now be applied in selected patients. For transthyretin amyloidosis (ATTR), the second most common form of amyloidosis with cardiac involvement, there is also significant progress in treatment. Until recently, we had no specific therapy for ATTR cardiomyopathy (ATTR-CM), though now disease-modifying therapies are available. Therapies that stabilize transthyretin, such as tafamidis, have been shown to improve outcomes for patients with ATTR-CM. Modern treatments that stop the synthesis of TTR through gene silencing, such as patisiran and inotersen, have shown positive results for patients with TTR amyloidosis. Significant progress has been made in the treatment of amyloid cardiomyopathy, and hopefully, we will see even more progress with the spread of those treatments. We now can be optimistic about patients with this disease.
- 23 April 2020
- Published by Springer Nature in Current Treatment Options in Oncology
- Vol. 21 (5) , 1-18
Open AccessAdvances in the Treatment of Cardiac Amyloidosis
Opinion statement: Cardiac amyloidosis is associated with a high mortality rate, a long delay between the first signs and the diagnosis but a short interval between diagnosis and death. This scenario has changed recently due to improved disease awareness among doctors and significant progress in diagnosis thanks to multimodal imaging and a multidisciplinary approach. Therefore, during the last few years, we have had access to specific therapies for those patients. Those therapies are quite different depending on the type of amyloidosis, but there has been real progress. Systemic light chain amyloidosis (AL) with cardiac involvement is the most common form of cardiac amyloidosis. The severity of heart disease dictates the prognosis in AL amyloidosis. Advances in chemotherapy and immunotherapy that suppress light chain production have improved the outcomes. These recent improvements in survival rates have enabled therapies such as implanted cardiac defibrillators and heart transplantation that were usually not indicated for patients with advanced light chain amyloid cardiomyopathy to now be applied in selected patients. For transthyretin amyloidosis (ATTR), the second most common form of amyloidosis with cardiac involvement, there is also significant progress in treatment. Until recently, we had no specific therapy for ATTR cardiomyopathy (ATTR-CM), though now disease-modifying therapies are available. Therapies that stabilize transthyretin, such as tafamidis, have been shown to improve outcomes for patients with ATTR-CM. Modern treatments that stop the synthesis of TTR through gene silencing, such as patisiran and inotersen, have shown positive results for patients with TTR amyloidosis. Significant progress has been made in the treatment of amyloid cardiomyopathy, and hopefully, we will see even more progress with the spread of those treatments. We now can be optimistic about patients with this disease.
- Open Access
- 24 January 2015
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 15 (1) , 1-4
Noncompaction cardiomyopathy: a substrate for a thromboembolic event
Noncompaction cardiomyopathy (NCC) is a rare genetic cardiomyopathy characterized by a thin, compacted epicardial layer and an extensive noncompacted endocardial layer. The clinical manifestations of this disease include ventricular arrhythmia, heart failure, and systemic thromboembolism. A 43-year-old male was anticoagulated by pulmonary thromboembolism for 1 year when he developed progressive dyspnea. Cardiovascular magnetic resonance imaging showed severe biventricular trabeculation with an ejection fraction of 15%, ratio of maximum noncompacted/compacted diastolic myocardial thickness of 3.2 and the presence of exuberant biventricular apical thrombus. Still under discussion is the issue of which patients and when they should be anticoagulated. It is generally recommended to those presenting ventricular systolic dysfunction, antecedent of systemic embolism, presence of cardiac thrombus and atrial fibrillation. In clinical practice the patients with NCC and ventricular dysfunction have been given oral anticoagulation, although there are no clinical trials showing the real safety and benefit of this treatment.
- 24 January 2015
- Published by Springer Nature in BMC Cardiovascular Disorders
- Vol. 15 (1) , 1-4
Open AccessNoncompaction cardiomyopathy: a substrate for a thromboembolic event
Noncompaction cardiomyopathy (NCC) is a rare genetic cardiomyopathy characterized by a thin, compacted epicardial layer and an extensive noncompacted endocardial layer. The clinical manifestations of this disease include ventricular arrhythmia, heart failure, and systemic thromboembolism. A 43-year-old male was anticoagulated by pulmonary thromboembolism for 1 year when he developed progressive dyspnea. Cardiovascular magnetic resonance imaging showed severe biventricular trabeculation with an ejection fraction of 15%, ratio of maximum noncompacted/compacted diastolic myocardial thickness of 3.2 and the presence of exuberant biventricular apical thrombus. Still under discussion is the issue of which patients and when they should be anticoagulated. It is generally recommended to those presenting ventricular systolic dysfunction, antecedent of systemic embolism, presence of cardiac thrombus and atrial fibrillation. In clinical practice the patients with NCC and ventricular dysfunction have been given oral anticoagulation, although there are no clinical trials showing the real safety and benefit of this treatment.
- 1 November 2013
- Published by Elsevier in Cardiovascular Pathology
- Vol. 22 (6) , 503-504
Left ventricular basal region involvement in noncompaction cardiomyopathy
- 1 November 2013
- Published by Elsevier in Cardiovascular Pathology
- Vol. 22 (6) , 503-504
Left ventricular basal region involvement in noncompaction cardiomyopathy